Front Row Advisors’s Definium Therapeutics DFTX Stock Holding History

Front Row Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-133	Closed	–	–	925
2023 Q1	$0	Hold	133	–	–	﹤0.01%	934
2022 Q4	$0	Hold	133	–	–	﹤0.01%	920
2022 Q3	$1K	Hold	133	–	–	﹤0.01%	891
2022 Q2	$1K	Hold	133	–	–	﹤0.01%	895
2022 Q1	$2K	Hold	133	–	–	﹤0.01%	862
2021 Q4	$3K	Hold	133	–	–	﹤0.01%	833
2021 Q3	$5K	Hold	133	–	–	﹤0.01%	743
2021 Q2	$5K	Buy	+133	New	+$6.98K	﹤0.01%	745

Other funds holding DFTX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Front Row Advisors's DFTX Position: Q2 2023 in Review

Front Row Advisors sold out of Definium Therapeutics (DFTX) in Q2 2023, closing a stake of 133 shares.

Front Row Advisors first reported a position in DFTX in Q2 2021 and held it in 8 quarters. The position peaked at $5K in Q3 2021. 84 funds tracked by Wall St. Rank hold DFTX as of Q2 2023.

Front Row Advisors reported no remaining Definium Therapeutics position as of Q2 2023 after selling out during the quarter.
Front Row Advisors sold 133 Definium Therapeutics shares in Q2 2023.
Front Row Advisors first reported a position in Definium Therapeutics in Q2 2021 and held it in 8 quarters.
Front Row Advisors's Definium Therapeutics position peaked at $5K in Q3 2021.
84 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2023.

Based on Front Row Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.